Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death globally.
• Immunotherapy offers hope for metastatic CRC but faces challenges from tumor heterogeneity.
• Patient responses to immunotherapy vary significantly due to inter- and intra-tumor differences.

Purpose of the Study:

• To review the latest findings in colorectal cancer immunotherapy.
• To elaborate on tumor heterogeneity as a bottleneck in CRC immunotherapy.
• To discuss advances in personalized immunotherapy for overcoming CRC heterogeneity.

Main Methods:

• Review of recent scientific literature on colorectal cancer immunotherapy.
• Analysis of molecular subtyping, mutation-based classification, and immunoscoring in CRC.
• Exploration of sequencing and multi-omics techniques for patient classification.

Main Results:

• Tumor heterogeneity significantly impacts immunotherapy success in colorectal cancer.
• Advanced classification methods improve patient grouping and immunotherapy response.
• Personalized immunotherapy, focusing on tumor-specific neoantigens, shows potential.

Conclusions:

• Overcoming colorectal cancer heterogeneity is crucial for improving immunotherapy outcomes.
• Personalized, neoantigen-based immunotherapy represents a new era for treating heterogeneous tumors like CRC.
• Multi-omics and advanced sequencing techniques are key to precise patient classification and tailored treatments.